ORY-2001 (vafidemstat), combining properties of a KDM1A inhibitor and a monoamine oxidase B (MAO B) inhibitor [142], was reported to reduce agitation and aggression, as well as cause a rise in the total Neuropsychiatric Index and measures of caregiver burden in an open-label study in 12 people with Alzheimer’s disease (a six-month course of 1.2 mg of the drug daily) [143]. This evidence concerns the gene MAOB and early-onset autosomal dominant Alzheimer disease.